[go: up one dir, main page]

SMP200700051B - Imidazochinoline come inibitori di lipide chinasi - Google Patents

Imidazochinoline come inibitori di lipide chinasi

Info

Publication number
SMP200700051B
SMP200700051B SM200700051T SM200700051T SMP200700051B SM P200700051 B SMP200700051 B SM P200700051B SM 200700051 T SM200700051 T SM 200700051T SM 200700051 T SM200700051 T SM 200700051T SM P200700051 B SMP200700051 B SM P200700051B
Authority
SM
San Marino
Prior art keywords
imidazoquinolines
kinase inhibitors
lipid kinase
lipid
inhibitors
Prior art date
Application number
SM200700051T
Other languages
English (en)
Other versions
SMAP200700051A (it
Inventor
Carlos Garcia-Echeverria
Frederic Stauffer
Pascal Furet
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34834420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMP200700051(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SMP200700051B publication Critical patent/SMP200700051B/it
Publication of SMAP200700051A publication Critical patent/SMAP200700051A/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
SM200700051T 2005-05-20 2006-05-18 Imidazochinoline come inibitori di lipide chinasi SMAP200700051A (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0510390.8A GB0510390D0 (en) 2005-05-20 2005-05-20 Organic compounds
PCT/EP2006/004725 WO2006122806A2 (en) 2005-05-20 2006-05-18 1,3-dihydro-imidazo [4,5-c] quinolin-2-ones as lipid kinase inhibitors

Publications (2)

Publication Number Publication Date
SMP200700051B true SMP200700051B (it) 2007-11-28
SMAP200700051A SMAP200700051A (it) 2007-11-28

Family

ID=34834420

Family Applications (1)

Application Number Title Priority Date Filing Date
SM200700051T SMAP200700051A (it) 2005-05-20 2006-05-18 Imidazochinoline come inibitori di lipide chinasi

Country Status (37)

Country Link
US (4) US7667039B2 (it)
EP (3) EP1888578B8 (it)
JP (2) JP5220591B2 (it)
KR (1) KR101237575B1 (it)
CN (2) CN101495477A (it)
AR (2) AR054127A1 (it)
AT (1) ATE535526T1 (it)
AU (1) AU2006249071B2 (it)
BR (1) BRPI0610321B8 (it)
CA (1) CA2608496C (it)
CR (1) CR9504A (it)
CY (2) CY1112369T1 (it)
DK (3) DK1888578T3 (it)
EA (1) EA013434B1 (it)
ES (3) ES2391161T3 (it)
GB (1) GB0510390D0 (it)
GE (1) GEP20105054B (it)
GT (1) GT200600193A (it)
HR (2) HRP20130794T1 (it)
IL (2) IL187003A (it)
JO (1) JO2751B1 (it)
MA (1) MA29462B1 (it)
MX (1) MX2007014380A (it)
MY (1) MY147442A (it)
NI (1) NI200700296A (it)
NO (1) NO340584B1 (it)
NZ (1) NZ562890A (it)
PE (1) PE20070004A1 (it)
PL (2) PL2270008T3 (it)
PT (2) PT2270008E (it)
SI (2) SI1888578T1 (it)
SM (1) SMAP200700051A (it)
TN (1) TNSN07431A1 (it)
TW (1) TWI383982B (it)
UA (1) UA92490C2 (it)
WO (1) WO2006122806A2 (it)
ZA (1) ZA200709074B (it)

Families Citing this family (482)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080269846A1 (en) * 2003-03-14 2008-10-30 Light Sciences Oncology, Inc. Device for treatment of blood vessels using light
CN2885311Y (zh) 2006-01-18 2007-04-04 郑成福 经尿道光动力疗法前列腺治疗仪
US10376711B2 (en) * 2003-03-14 2019-08-13 Light Sciences Oncology Inc. Light generating guide wire for intravascular use
AU2004266641A1 (en) 2003-08-12 2005-03-03 3M Innovative Properties Company Oxime substituted imidazo-containing compounds
EP1658076B1 (en) 2003-08-27 2013-03-06 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
US20050054665A1 (en) 2003-09-05 2005-03-10 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
ES2544477T3 (es) 2003-10-03 2015-08-31 3M Innovative Properties Company Imidazoquinolinas sustituidas con alcoxi
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
US7897767B2 (en) 2003-11-14 2011-03-01 3M Innovative Properties Company Oxime substituted imidazoquinolines
JP2007511535A (ja) 2003-11-14 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー ヒドロキシルアミン置換イミダゾ環化合物
RU2409576C2 (ru) 2003-11-25 2011-01-20 3М Инновейтив Пропертиз Компани Системы, содержащие имидазольное кольцо с заместителями, и способы их получения
WO2005066170A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
CA2551399A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
EP1730143A2 (en) 2004-03-24 2006-12-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
CA2592904C (en) 2004-12-30 2015-04-07 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
AU2005326708C1 (en) 2004-12-30 2012-08-30 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
WO2006086634A2 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007063760A1 (ja) * 2005-11-30 2007-06-07 Mitsubishi Chemical Corporation 有機化合物、電荷輸送材料、電荷輸送材料用組成物および有機電界発光素子
JP5250967B2 (ja) * 2005-11-30 2013-07-31 三菱化学株式会社 有機化合物、電荷輸送材料、電荷輸送材料用組成物および有機電界発光素子
KR101391900B1 (ko) 2005-12-13 2014-05-02 인사이트 코포레이션 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘
US8329721B2 (en) * 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
CN102993202A (zh) * 2006-11-20 2013-03-27 诺瓦提斯公司 2-甲基-2-[4-(3-甲基-2-氧代-8-喹啉-3-基-2,3-二氢-咪唑并[4,5-c]喹啉-1-基)-苯基]-丙腈的盐和晶型
CN101616672A (zh) * 2007-02-20 2009-12-30 诺瓦提斯公司 作为脂质激酶和mTOR双重抑制剂的咪唑并喹啉类
US20080234262A1 (en) * 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
WO2008157208A2 (en) 2007-06-13 2008-12-24 Incyte Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
EP2170338A2 (en) * 2007-07-06 2010-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dna-pkcs modulates energy regulation and brain function
PL2182948T3 (pl) * 2007-07-24 2013-07-31 Novartis Ag Zastosowanie imidazochinolin do leczenia chorób EGFR-zależnych albo chorób wykazujących nabytą oporność wobec środków ukierunkowanych na członków rodziny EGFR
US20090082387A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
JP2011506455A (ja) * 2007-12-13 2011-03-03 ノバルティス アーゲー 癌を処置するための治療薬の組み合わせ剤
BRPI0909082A2 (pt) * 2008-03-26 2019-02-26 Novartis Ag imidazoquinolinas e derivados de pirimidina como moduladores potentes de processos angiogênicos acionados por vegf
KR20110028651A (ko) * 2008-07-11 2011-03-21 노파르티스 아게 (ａ) 포스포이노시타이드 3-키나제 억제제 및 (ｂ) ｒａｓ/ｒａｆ/ｍｅｋ 경로의 조절제의 조합물
EP2356120B1 (en) 2008-09-30 2016-10-12 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
AU2009299927B2 (en) * 2008-10-01 2013-05-30 Novartis Ag Smoothened antagonism for the treatment of hedgehog pathway-related disorders
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
EP2350053B1 (en) 2008-10-17 2013-12-11 Whitehead Institute For Biomedical Research Modulators of MTOR Complexes
WO2010108013A1 (en) * 2009-03-18 2010-09-23 The Trustees Of The University Of Pennsylvania Compositions and methods for treating asthma and other lung diseases
JP5766177B2 (ja) 2009-03-27 2015-08-19 ベトディーシー，インコーポレイテッド ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
WO2010130779A2 (en) * 2009-05-15 2010-11-18 Novartis Ag COMBINATION OF A PBOSPBOINOSITKLE 3-KSπASE INHIBITOR AND AN ANTIDIABETIC COMPOUND
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
DK2432472T3 (da) 2009-05-22 2019-11-18 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- eller heptan-nitril som jak-inhibitorer
EA020715B1 (ru) * 2009-06-04 2015-01-30 Новартис Аг ПРОИЗВОДНЫЕ 1H-ИМИДАЗО[4,5-c]ХИНОЛИНОНА
US20100311714A1 (en) * 2009-06-04 2010-12-09 Pascal Furet 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS
CA2766967A1 (en) * 2009-06-30 2011-01-06 Piramal Life Sciences Limited Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation
EP2532659A1 (en) 2009-07-07 2012-12-12 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
US20110008372A1 (en) * 2009-07-08 2011-01-13 Light Sciences Oncology, Inc. Enhancement of light activated drug therapy through combination with other therapeutic agents
WO2011007819A1 (ja) 2009-07-17 2011-01-20 塩野義製薬株式会社 ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
PH12015502575A1 (en) 2010-03-10 2017-04-24 Incyte Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
CN102821759A (zh) 2010-03-30 2012-12-12 诺华有限公司 用于治疗具有慢性活性b细胞受体信号传导的b细胞淋巴瘤的pkc抑制剂
EP3087972A1 (en) 2010-05-21 2016-11-02 Incyte Holdings Corporation Topical formulation for a jak inhibitor
DE102010025786A1 (de) * 2010-07-01 2012-01-05 Merck Patent Gmbh Pyrazolochinoline
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
KR20130043198A (ko) * 2010-07-16 2013-04-29 피라말 엔터프라이지즈 리미티드 키나제 억제제로서 치환된 이미다조퀴놀린 유도체
CN102372712B (zh) * 2010-08-18 2013-10-23 山东轩竹医药科技有限公司 咪唑并二氮杂萘类PI3K和mTOR双重抑制剂
CN102372711B (zh) * 2010-08-18 2014-09-17 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂
PL2606070T3 (pl) 2010-08-20 2017-06-30 Novartis Ag Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
CN102382128A (zh) * 2010-08-27 2012-03-21 山东轩竹医药科技有限公司 三并环的PI3K和mTOR双重抑制剂
DE102010035744A1 (de) * 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
AR083267A1 (es) * 2010-10-04 2013-02-13 Novartis Ag Combinaciones farmaceuticas
WO2012068483A1 (en) 2010-11-18 2012-05-24 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment based on hypoxic status
JP2014503500A (ja) 2010-11-18 2014-02-13 シンタ ファーマスーティカルズ コーポレーション 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択
CA2818545C (en) 2010-11-19 2019-04-16 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CN103415515B (zh) 2010-11-19 2015-08-26 因塞特公司 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
PH12013501098A1 (en) * 2010-12-03 2013-07-08 Novartis Ag Pharmaceutical compositions
RU2013130907A (ru) 2010-12-06 2015-01-20 Пирамал Энтерпрайзис Лимитед Замещенные имидазохинолиновые производные
CN103261186A (zh) 2010-12-13 2013-08-21 诺瓦提斯公司 二聚化iap抑制剂
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
US9358236B2 (en) 2011-02-16 2016-06-07 Novartis Ag Combinations of therapeutic agents for use in the treatment of neurodegenerative diseases
PL2675451T3 (pl) 2011-02-18 2016-05-31 Novartis Pharma Ag Terapia skojarzona z inhibitorem mTOR/JAK
US20120238562A1 (en) * 2011-03-09 2012-09-20 Cedars-Sinai Medical Center Treatment of cancer by targeting molecules that influence mst1/stk4 signaling
JP6042406B2 (ja) 2011-03-28 2016-12-14 メイ プハルマ，インコーポレーテッド （α−置換アラルキルアミノ及びヘテロアリールアルキルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、それらを含む医薬組成物、並びに増殖性疾患の治療で使用するためのこれらの化合物
US9475812B2 (en) 2011-06-04 2016-10-25 Xuanzhu Pharma Co., Ltd. Pyridonaphthyridine type dual PI3K and mTOR inhibitor and its preparation and use
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
JP5832647B2 (ja) 2011-07-01 2015-12-16 ノバルティス アーゲー がんの治療における使用のためのｃｄｋ４／６阻害剤およびｐｉ３ｋ阻害剤を含む併用療法
AP2014007400A0 (en) 2011-07-13 2014-01-31 Novartis Ag 4-Piperidinyl compounds for use as tankyrase inhibitors
US9181266B2 (en) 2011-07-13 2015-11-10 Novartis Ag 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
US9227982B2 (en) 2011-07-13 2016-01-05 Novartis Ag 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors
WO2013023119A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
WO2013066483A1 (en) 2011-08-31 2013-05-10 Novartis Ag Synergistic combinations of pi3k- and mek-inhibitors
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CN103012398B (zh) * 2011-09-19 2015-10-14 上海恒瑞医药有限公司 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用
JP2014532057A (ja) 2011-09-30 2014-12-04 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 粘表皮癌を治療する方法
WO2013050921A1 (en) 2011-10-03 2013-04-11 Piramal Enterprises Limited Hollow polymer microspheres as three-dimensional cell culture matrix
CN103030637A (zh) * 2011-10-10 2013-04-10 上海恒瑞医药有限公司 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用
EP2768813A1 (en) 2011-10-21 2014-08-27 Novartis AG Quinazoline derivatives as pi3k modulators
JP2014532647A (ja) * 2011-10-28 2014-12-08 ノバルティス アーゲー 消化管間質腫瘍を治療する方法
MX2014005927A (es) 2011-11-15 2014-06-05 Novartis Ag Combinacion de un inhibidor de la fosfoinositida-3-cinasa y un modulador de la senda del transductor y activador de la señal de transcripcion 5 de la cinasa janus 2.
WO2013071698A1 (zh) 2011-11-17 2013-05-23 山东轩竹医药科技有限公司 三环类PI3K和/或mTOR抑制剂
WO2013084138A1 (en) 2011-12-05 2013-06-13 Novartis Ag Cyclic urea derivatives as androgen receptor antagonists
AU2012349735B2 (en) 2011-12-05 2016-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
EP2788382A2 (en) 2011-12-05 2014-10-15 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
CA2857302C (en) 2011-12-15 2020-08-25 Novartis Ag Use of inhibitors of the activity or function of pi3k
EP2794594A1 (en) 2011-12-22 2014-10-29 Novartis AG Quinoline derivatives
PE20141598A1 (es) 2011-12-22 2014-11-14 Novartis Ag Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
BR112014016870A2 (pt) 2012-01-09 2017-06-27 Huesken Dieter composições orgânicas para tratar doenças relacionadas com beta-catenina
WO2013154778A1 (en) 2012-04-11 2013-10-17 Dana-Farber Cancer Institute, Inc. Host targeted inhibitors of dengue virus and other viruses
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
KR20160027218A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
WO2013184621A1 (en) 2012-06-06 2013-12-12 Novartis Ag Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
WO2013192367A1 (en) 2012-06-22 2013-12-27 Novartis Ag Neuroendocrine tumor treatment
WO2014006115A1 (en) 2012-07-06 2014-01-09 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
HK1211476A1 (en) * 2012-08-16 2016-05-27 Novartis Ag Combination of pi3k inhibitor and c-met inhibitor
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
EP3949953A1 (en) 2012-11-15 2022-02-09 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
EP3251673A1 (en) 2012-12-13 2017-12-06 IP Gesellschaft für Management mbH Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
US20150376161A1 (en) 2013-01-29 2015-12-31 Avexxin As Antiiflammatory and antitumor 2-oxothiazoles abd 2-oxothiophenes compounds
DK2958907T3 (en) 2013-02-19 2018-06-06 Novartis Ag Thus, benzothiophene derivatives and compositions as selective estrogen receptor degraders
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
SG11201505896YA (en) 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
BR112015021458B1 (pt) 2013-03-06 2022-06-07 Incyte Holdings Corporation "processos e intermediários para preparar {1-{1-[3-flúor2-(trifluormetil)isonicotinoil] piperidin-4-il}-3-[4-(7hpirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrila, útil no tratamento de doenças relacionadas com a atividade de janus quinases
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
WO2014141118A1 (en) 2013-03-14 2014-09-18 Piramal Enterprises Limited Imidazo[4,5-c]quinoline derivatives and uses thereof
MX366978B (es) 2013-03-15 2019-08-01 Novartis Ag Conjugados de anticuerpo - farmaco.
PT2976106T (pt) 2013-03-21 2021-05-26 Array Biopharma Inc Terapia de combinação que compreende um inibidor de b-raf e um segundo inibidor
WO2014177915A1 (en) 2013-05-01 2014-11-06 Piramal Enterprises Limited Cancer combination therapy using imidazo[4,5-c]quinoline derivatives
AU2014282798A1 (en) * 2013-06-18 2015-12-03 Novartis Ag Pharmaceutical combinations
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
WO2015021153A1 (en) 2013-08-07 2015-02-12 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
US10500232B2 (en) 2013-08-26 2019-12-10 The J. David Gladstone Ins., a testamentary trust established under the Will of J. David Gladstone Small molecule cellular reprogramming to generate neuronal cells
CN104418858B (zh) 2013-08-30 2018-12-11 浙江医药股份有限公司新昌制药厂 2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
JP2016537345A (ja) 2013-11-13 2016-12-01 ノバルティス アーゲー 免疫応答を増強するためのｍＴＯＲ阻害剤
US20160264570A1 (en) * 2013-11-15 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Method of blocking transmission of malarial parasite
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
CA3225453A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN105899493B (zh) 2014-01-17 2019-03-29 诺华股份有限公司 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
CN105899491B (zh) 2014-01-17 2019-04-02 诺华股份有限公司 用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
ES2921874T3 (es) 2014-02-28 2022-09-01 Nimbus Lakshmi Inc Inhibidores de TYK2 y usos de los mismos
ME03558B (me) 2014-03-14 2020-07-20 Novartis Ag Molekuli anti-lag-3 antiтela i njihove upotrebe
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
FI3888674T3 (fi) 2014-04-07 2024-07-02 Novartis Ag Syövän hoito käyttäen kimeeristä anti-cd19-antigeenireseptoria
WO2015162584A1 (en) 2014-04-24 2015-10-29 Novartis Ag Crystalline forms of the sulfate salt of n-[5-(3-imidazol-1-yl-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]-acetamide
NO2714752T3 (it) * 2014-05-08 2018-04-21
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
CN105311030B (zh) 2014-06-06 2020-03-24 正大天晴药业集团股份有限公司 用于抗肿瘤的螺取代化合物
CN105311029A (zh) 2014-06-06 2016-02-10 正大天晴药业集团股份有限公司 抗肿瘤活性的喹啉衍生物
AU2015290007B2 (en) * 2014-07-14 2019-11-21 Advenchen Pharmaceuticals, Nanjing Ltd. Fused quinoline compunds as pi3k, mTor inhibitors
ES2729202T3 (es) 2014-07-16 2019-10-30 Dana Farber Cancer Inst Inc Et Al Inhibición de HER3 en cánceres ováricos serosos de grado bajo
BR112017001242A2 (pt) 2014-07-21 2017-12-05 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico a cd33
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
US20170209492A1 (en) 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
KR20170040249A (ko) 2014-08-12 2017-04-12 노파르티스 아게 항-cdh6 항체 약물 접합체
AU2015303835B2 (en) 2014-08-12 2020-04-09 Monash University Lymph directing prodrugs
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
JP6919118B2 (ja) 2014-08-14 2021-08-18 ノバルティス アーゲー ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
MY189028A (en) 2014-08-19 2022-01-20 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
CA2961636A1 (en) 2014-09-17 2016-03-24 Boris ENGELS Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EA201790737A1 (ru) 2014-10-03 2017-08-31 Новартис Аг Комбинированная терапия
CN106973568B (zh) 2014-10-08 2021-07-23 诺华股份有限公司 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MX389663B (es) 2014-10-14 2025-03-20 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
US10532106B2 (en) 2014-10-29 2020-01-14 Bicyclerd Limited Bicyclic peptide ligands specific for MT1-MMP
PE20170912A1 (es) 2014-11-14 2017-07-12 Novartis Ag Conjugados de anticuerpo-farmaco
JP6695875B2 (ja) 2014-11-20 2020-05-20 カウンシル・オブ・サイエンティフィック・アンド・インダストリアル・リサーチ 抗がん剤としての新規な１，３，５−トリアジン系ｐｉ３ｋ阻害剤及びその製造方法
US10307412B2 (en) 2014-12-09 2019-06-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Quinoline derivative against non-small cell lung cancer
CN108367003B (zh) 2014-12-12 2022-01-21 麻省总医院 乳腺癌脑转移的治疗
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
ES2722048T3 (es) 2014-12-23 2019-08-07 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos
TWI744225B (zh) 2015-02-27 2021-11-01 美商林伯士拉克許米公司 酪胺酸蛋白質激酶２（ｔｙｋ２）抑制劑及其用途
CA2975277A1 (en) 2015-03-04 2016-09-09 Dana-Farber Cancer Institute, Inc. Tricyclic kinase inhibitors of melk and methods of use
US10449211B2 (en) 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
FR3033499A1 (fr) 2015-03-11 2016-09-16 Centre Leon-Berard Composition pour le traitement des tumeurs neuroendocrines pancreatiques
RU2017134379A (ru) 2015-03-25 2019-04-03 Новартис Аг Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4
CA2981365A1 (en) 2015-04-02 2016-10-06 Merck Patent Gmbh Imidazolonylquinolines and the use thereof as atm kinase inhibitors
ES2876974T3 (es) 2015-04-07 2021-11-15 Novartis Ag Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
CN108473957B (zh) 2015-04-17 2024-07-16 诺华股份有限公司 改善嵌合抗原受体表达细胞的功效和扩增的方法
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
US9751859B2 (en) 2015-05-04 2017-09-05 Advenchen Pharmaceuticals, LLC Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
CN107847491A (zh) 2015-05-20 2018-03-27 诺华公司 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
EP3310813A1 (en) 2015-06-17 2018-04-25 Novartis AG Antibody drug conjugates
EP3310771B1 (en) 2015-06-19 2020-07-22 Novartis AG Compounds and compositions for inhibiting the activity of shp2
EP3310779B1 (en) 2015-06-19 2019-05-08 Novartis AG Compounds and compositions for inhibiting the activity of shp2
CN112625028B (zh) 2015-06-19 2024-10-29 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
WO2017004134A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
AU2016293841B2 (en) * 2015-07-11 2020-10-08 Advenchen Pharmaceuticals, LLC Fused quinoline compunds as pi3k/mTor inhibitors
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
AU2016314082B2 (en) 2015-08-28 2019-07-25 Novartis Ag Mdm2 inhibitors and combinations thereof
EP4327809A3 (en) 2015-09-02 2024-04-17 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
CA2997106C (en) 2015-09-08 2024-06-04 Monash University Lymph directing prodrugs
US10683308B2 (en) 2015-09-11 2020-06-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
ES2941969T3 (es) 2015-10-23 2023-05-29 Navitor Pharm Inc Moduladores de la interacción de Sestrina-GATOR2 y sus usos
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
SI3370768T1 (sl) 2015-11-03 2022-04-29 Janssen Biotech, Inc. Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
HK1253737A1 (zh) 2015-12-03 2019-06-28 Novartis Ag 在ctdna中具有pik3ca突变的预选患者中用pi3k抑制剂治疗癌症
WO2017106352A1 (en) 2015-12-14 2017-06-22 Raze Therapeutics, Inc. Caffeine inhibitors of mthfd2 and uses thereof
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
WO2017156179A1 (en) 2016-03-09 2017-09-14 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
HUE055197T2 (hu) 2016-03-09 2021-11-29 Raze Therapeutics Inc 3-Foszfoglicerát-dehidrogenáz inhibitorok és alkalmazásuk
GB201604316D0 (en) * 2016-03-14 2016-04-27 Avexxin As Combination therapy
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
CA3019394A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN107296811B (zh) 2016-04-15 2022-12-30 正大天晴药业集团股份有限公司 一种用于治疗胃癌的喹啉衍生物
US10577362B2 (en) 2016-05-04 2020-03-03 Genoscience Pharma Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases
WO2017216706A1 (en) 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
US11091489B2 (en) 2016-06-20 2021-08-17 Novartis Ag Crystalline forms of a triazolopyrimidine compound
EP3472161B1 (en) 2016-06-20 2020-03-25 Novartis AG Triazolopyridine compounds and uses thereof
EP3472166A1 (en) 2016-06-20 2019-04-24 Novartis AG Imidazopyrimidine compounds useful for the treatment of cancer
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
CN109562106B (zh) 2016-06-21 2023-03-21 X4 制药有限公司 Cxcr4抑制剂及其用途
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
JP2019519593A (ja) 2016-07-06 2019-07-11 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｃｈｉｇａｎ ＭＥＫ／ＰＩ３Ｋ及びｍＴＯＲ／ＭＥＫ／ＰＩ３Ｋ生物学的経路の多官能性阻害剤、並びに同多官能性阻害剤を用いた治療方法
US11365252B2 (en) 2016-07-20 2022-06-21 University Of Utah Research Foundation CD229 CAR T cells and methods of use thereof
CA3037582A1 (en) 2016-09-21 2018-03-29 Avexxin As Pharmaceutical composition
US20200055917A1 (en) 2016-09-27 2020-02-20 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules
EP3523331A1 (en) 2016-10-07 2019-08-14 Novartis AG Chimeric antigen receptors for the treatment of cancer
EP3526220B1 (en) 2016-10-13 2025-06-11 The United States of America, as represented by the Secretary, Department of Health and Human Services Compounds and method for blocking transmission of malarial parasite
EP3848370B1 (en) 2016-10-14 2025-05-07 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
IL266109B2 (en) 2016-10-21 2025-05-01 Nimbus Lakshmi Inc Tyk2 inhibitors and uses thereof
EP3538091A4 (en) 2016-11-08 2020-06-10 Navitor Pharmaceuticals, Inc. PHENYL AMINO PIPERIDINE MTORC INHIBITORS AND USES THEREOF
WO2018092064A1 (en) 2016-11-18 2018-05-24 Novartis Ag Combinations of mdm2 inhibitors and bcl-xl inhibitors
CN110114070A (zh) 2016-11-23 2019-08-09 诺华公司 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
WO2018106636A1 (en) 2016-12-05 2018-06-14 Raze Therapeutics, Inc. Shmt inhibitors and uses thereof
EP3554558A4 (en) 2016-12-14 2020-10-28 Tarveda Therapeutics, Inc. HSP90 TARGETING CONJUGATES AND FORMULATIONS OF THE LATEST
HUE054548T2 (hu) 2016-12-20 2021-09-28 Astrazeneca Ab Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
EP3558955B1 (en) 2016-12-22 2021-08-11 Amgen Inc. Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
JP2020502238A (ja) 2016-12-23 2020-01-23 バイスクルアールディー・リミテッド 新規連結構造を有するペプチド誘導体
US10624968B2 (en) 2017-01-06 2020-04-21 Bicyclerd Limited Compounds for treating cancer
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
US11179413B2 (en) 2017-03-06 2021-11-23 Novartis Ag Methods of treatment of cancer with reduced UBB expression
IL269036B2 (en) 2017-03-08 2023-03-01 Nimbus Lakshmi Inc tyk2 inhibitors, uses and methods for their production
EP3375784A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aza-dihydro-acridone derivatives
EP3375778A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aryl-piperidine derivatives
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
US11339144B2 (en) 2017-04-10 2022-05-24 Navitor Pharmaceuticals, Inc. Heteroaryl Rheb inhibitors and uses thereof
ES3040534T3 (en) 2017-04-26 2025-11-03 Navitor Pharm Inc Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
US10857196B2 (en) 2017-04-27 2020-12-08 Bicycletx Limited Bicyclic peptide ligands and uses thereof
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
IL322309A (en) 2017-05-24 2025-09-01 Novartis Ag IL2 antibody grafted proteins and methods of use in cancer treatment
US20200362058A1 (en) 2017-05-24 2020-11-19 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
EP3658557B1 (en) 2017-07-28 2024-06-05 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
AU2018316175B2 (en) 2017-08-11 2023-02-23 The Regents Of The University Of Michigan Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K3k/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds
US20200291096A1 (en) 2017-08-14 2020-09-17 Bicyclerd Limited Bicyclic peptide ligand sting conjugates and uses thereof
JP2020531414A (ja) 2017-08-14 2020-11-05 エムイーアイ ファーマ，インク． 併用療法
WO2019034868A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
EP3675838A4 (en) 2017-08-29 2021-04-21 PureTech LYT, Inc. LIPID PRODRUGS DIRECTED TO THE LYMPHATIC SYSTEM
EP3679040B1 (en) 2017-09-08 2022-08-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same
TWI851542B (zh) 2017-09-11 2024-08-11 美商克魯松藥物公司 Ｓｈｐ２之八氫環戊烷并[c]吡咯別構抑制劑
WO2019060742A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
EP3684366A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES OF THE LATEST
FI3688032T3 (fi) 2017-09-26 2025-12-09 Cero Therapeutics Holdings Inc Kimeerisiä nielaisureseptorimolekyylejä ja käyttömenetelmiä
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
EP3727362A4 (en) 2017-12-19 2021-10-06 PureTech LYT, Inc. MYCOPHENOLIC ACID LIPID PRODRUGS AND THEIR USES
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
IL312674A (en) 2018-01-29 2024-07-01 Merck Patent Gmbh GCN2 inhibitors and uses thereof
SG11202006701TA (en) 2018-01-29 2020-08-28 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
DK3746429T3 (da) 2018-01-30 2022-05-02 Incyte Corp Fremgangsmåder til fremstilling af (1-(3-fluor-2-(trifluormethyl)isonicotinyl)piperidin-4-on)
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
JP2021514953A (ja) 2018-02-23 2021-06-17 バイスクルテクス・リミテッド 多量体二環式ペプチドリガンド
CA3091202A1 (en) 2018-02-27 2019-09-06 Artax Biopharma Inc. Chromene derivatives as inhibitors of tcr-nck interaction
CN111936467B (zh) 2018-03-02 2022-02-18 正大天晴药业集团股份有限公司 作为c-Met激酶抑制剂的化合物的结晶及其制备方法和用途
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib
WO2019191339A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
EP3774906A1 (en) 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
AU2019243154A1 (en) 2018-03-28 2020-10-01 Cero Therapeutics, Inc. Cellular immunotherapy compositions and uses thereof
CN112423759A (zh) 2018-03-30 2021-02-26 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
IL278122B2 (en) 2018-04-24 2024-01-01 Vertex Pharma Pteridinone compounds and uses thereof
ES2987356T3 (es) 2018-04-24 2024-11-14 Merck Patent Gmbh Compuestos antiproliferación y usos de los mismos
US20210047405A1 (en) 2018-04-27 2021-02-18 Novartis Ag Car t cell therapies with enhanced efficacy
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
AU2019262589B2 (en) 2018-05-04 2022-07-07 Amgen Inc. KRAS G12C inhibitors and methods of using the same
ES2995514T3 (en) 2018-05-04 2025-02-10 Amgen Inc Kras g12c inhibitors and methods of using the same
MX2020011907A (es) 2018-05-10 2021-01-29 Amgen Inc Inhibidores de kras g12c para el tratamiento de cancer.
CN108752336B (zh) * 2018-05-10 2021-06-04 常州润诺生物科技有限公司 咪唑并喹啉类衍生物及其用途
ES2938987T3 (es) 2018-06-01 2023-04-18 Amgen Inc Inhibidores de KRAS G12c y métodos de uso de los mismos
MX2020012204A (es) 2018-06-11 2021-03-31 Amgen Inc Inhibidores de kras g12c para tratar el cáncer.
CA3100390A1 (en) 2018-06-12 2020-03-12 Amgen Inc. Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
SG11202012447YA (en) 2018-06-15 2021-01-28 Navitor Pharm Inc Rapamycin analogs and uses thereof
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
AU2019344897B2 (en) 2018-09-18 2024-01-18 Nikang Therapeutics, Inc. Tri-substituted heteroaryl derivatives AS SRC homology-2 phosphatase inhibitors
CN113382986A (zh) 2018-09-25 2021-09-10 黑钻治疗公司 酪氨酸激酶抑制剂组合物、其制备方法和使用方法
JP2022502496A (ja) 2018-09-25 2022-01-11 ブラック ダイアモンド セラピューティクス，インコーポレイティド チロシンキナーゼ阻害剤組成物、作製方法、および使用方法
CA3113379A1 (en) 2018-09-29 2020-04-02 Novartis Ag Process of manufacture of a compound for inhibiting the activity of shp2
WO2020081508A1 (en) 2018-10-15 2020-04-23 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
US10919937B2 (en) 2018-10-23 2021-02-16 Bicycletx Limited Bicyclic peptide ligands and uses thereof
CN113164414A (zh) 2018-10-24 2021-07-23 纳维托制药有限公司 多晶型化合物和其用途
WO2020089811A1 (en) 2018-10-31 2020-05-07 Novartis Ag Dc-sign antibody drug conjugates
TWI680973B (zh) * 2018-11-09 2020-01-01 長庚學校財團法人長庚科技大學 嗜中性白血球發炎抑制劑及其用途
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
WO2020106640A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
WO2020112937A1 (en) 2018-11-30 2020-06-04 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
US11352350B2 (en) 2018-11-30 2022-06-07 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
CA3123871A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
WO2020132651A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
JP7676308B2 (ja) 2018-12-20 2025-05-14 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
MA54546A (fr) 2018-12-20 2022-03-30 Amgen Inc Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
WO2020128526A1 (en) 2018-12-21 2020-06-25 Bicycletx Limited Bicyclic peptide ligands specific for pd-l1
KR20210107731A (ko) 2018-12-21 2021-09-01 노파르티스 아게 Pmel17에 대한 항체 및 이의 접합체
AU2020212001A1 (en) 2019-01-23 2021-07-22 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
MX2021010323A (es) 2019-03-01 2021-12-10 Revolution Medicines Inc Compuestos bicíclicos de heterociclilo y usos de este.
JP2022528887A (ja) 2019-04-02 2022-06-16 バイスクルテクス・リミテッド バイシクルトキシンコンジュゲートおよびその使用
SG11202110829YA (en) 2019-04-05 2021-10-28 Kymera Therapeutics Inc Stat degraders and uses thereof
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
GB201906864D0 (en) 2019-05-15 2019-06-26 Avexxin As Combination therapy
GB201906867D0 (en) 2019-05-15 2019-06-26 Avexxin As Combination therapy
PH12021552922A1 (en) 2019-05-21 2022-04-04 Amgen Inc Solid state forms
KR20220034739A (ko) 2019-05-31 2022-03-18 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
WO2021001743A1 (en) 2019-07-02 2021-01-07 Effector Therapeutics, Inc. Translation inhibitors and uses thereof
GB201910644D0 (en) 2019-07-25 2019-09-11 Coegin Pharma As Cancer Treatment
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
JP7756070B2 (ja) 2019-08-02 2025-10-17 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤としてのピリジン誘導体
MX2022001295A (es) 2019-08-02 2022-02-22 Amgen Inc Inhibidores de kif18a.
AU2020324406A1 (en) 2019-08-02 2022-03-17 Amgen Inc. KIF18A inhibitors
JP7640521B2 (ja) 2019-08-02 2025-03-05 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
CN114787150A (zh) 2019-08-15 2022-07-22 黑钻治疗公司 炔基喹唑啉化合物
EP4028385A4 (en) 2019-09-11 2023-11-08 Vincere Biosciences, Inc. USP30 INHIBITORS AND USES THEREOF
US12215105B2 (en) 2019-09-13 2025-02-04 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
EP4031542B1 (en) 2019-09-18 2025-10-15 Merck Sharp & Dohme LLC Small molecule inhibitors of kras g12c mutant
US20230014730A1 (en) 2019-09-23 2023-01-19 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use
CN116574099A (zh) * 2019-09-23 2023-08-11 南京征祥医药有限公司 磷酸二酯酶抑制剂及用途
WO2021057853A1 (en) 2019-09-26 2021-04-01 Novartis Ag Aza-quinoline compounds and uses thereof
WO2021067875A1 (en) 2019-10-03 2021-04-08 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
EP4045047A1 (en) 2019-10-15 2022-08-24 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
AU2020369569A1 (en) 2019-10-24 2022-04-14 Amgen Inc. Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
UA129778C2 (uk) 2019-10-28 2025-07-30 Мерк Шарп Енд Доум Елелсі Низькомолекулярні інгібітори g12c-мутантного kras
CN119424423A (zh) 2019-10-31 2025-02-14 大鹏药品工业株式会社 4-氨基丁-2-烯酰胺衍生物及其盐
IL292612A (en) 2019-11-01 2022-07-01 Navitor Pharm Inc Treatment methods using mtorc1 modulator
CA3159561A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
AU2020379731A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
MX2022005525A (es) 2019-11-08 2022-06-08 Revolution Medicines Inc Compuestos de heteroarilo bicíclicos y usos de estos.
US12466825B2 (en) 2019-11-14 2025-11-11 Amgen Inc. Synthesis of KRAS G12C inhibitor compound
AR120456A1 (es) 2019-11-14 2022-02-16 Amgen Inc Síntesis mejorada del compuesto inhibidor de g12c de kras
CN111187181B (zh) * 2019-11-22 2023-05-05 吉林大学 一种2-(4-氨基苯基)-2-甲基丙腈化合物的制备方法
EP4065231A1 (en) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
TW202134234A (zh) 2019-12-05 2021-09-16 美商奈維特製藥公司 雷帕黴素類似物及其用途
WO2021126816A1 (en) 2019-12-16 2021-06-24 Amgen Inc. Dosing regimen of a kras g12c inhibitor
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
EP4076520A4 (en) 2019-12-17 2024-03-27 Kymera Therapeutics, Inc. Irak degraders and uses thereof
BR112022012410A2 (pt) 2019-12-23 2022-08-30 Kymera Therapeutics Inc Degradadores smarca e usos dos mesmos
MX2022008305A (es) 2020-01-07 2022-08-08 Revolution Medicines Inc Dosificacion de inhibidores de shp2 y metodos de tratamiento del cancer.
WO2021159021A1 (en) 2020-02-05 2021-08-12 Puretech Lyt, Inc. Lipid prodrugs of neurosteroids
BR112022017727A2 (pt) 2020-03-03 2022-11-16 Pic Therapeutics Inc Inibidores de eif4e e usos dos mesmos
PH12022552458A1 (en) 2020-03-19 2024-01-22 Kymera Therapeutics Inc Mdm2 degraders and uses thereof
WO2021195206A1 (en) 2020-03-24 2021-09-30 Black Diamond Therapeutics, Inc. Polymorphic forms and related uses
US20230181536A1 (en) 2020-04-24 2023-06-15 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
US20230174518A1 (en) 2020-04-24 2023-06-08 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
US20230250110A1 (en) 2020-06-03 2023-08-10 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
TW202214253A (zh) 2020-06-18 2022-04-16 美商銳新醫藥公司 延遲、預防及治療對ｒａｓ抑制劑之後天抗性之方法
JP2023539715A (ja) 2020-06-24 2023-09-19 アストラゼネカ ユーケー リミテッド 抗体－薬物コンジュゲートとａｔｍ阻害剤との組合わせ
KR20230031926A (ko) 2020-07-15 2023-03-07 다이호야쿠힌고교 가부시키가이샤 종양의 치료에 사용되는 피리미딘 화합물을 포함하는 조합
AR123185A1 (es) 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
WO2022036285A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
WO2022036287A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Anti-cd72 chimeric receptors and uses thereof
WO2022036265A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Chimeric tim receptors and uses thereof
KR20230074721A (ko) 2020-08-17 2023-05-31 바이사이클티엑스 리미티드 Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도
WO2022043556A1 (en) 2020-08-31 2022-03-03 Novartis Ag Stable radiopharmaceutical composition
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
CA3187757A1 (en) 2020-09-03 2022-03-24 Ethan AHLER Use of sos1 inhibitors to treat malignancies with shp2 mutations
PE20231207A1 (es) 2020-09-15 2023-08-17 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer
AU2020468487B2 (en) * 2020-09-21 2024-02-29 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo(4,5-c) quinolin-2-one compounds with blood-brain barrier penetrable capability
EP4232425A4 (en) 2020-10-23 2024-07-24 Nimbus Clotho, Inc. Ctps1 inhibitors and uses thereof
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
CA3200814A1 (en) 2020-12-02 2022-06-09 Alfredo C. Castro Tead inhibitors and uses thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
WO2022140472A1 (en) 2020-12-22 2022-06-30 Nikang Therapeutics, Inc. Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
TW202241891A (zh) 2020-12-30 2022-11-01 美商凱麥拉醫療公司 Irak降解劑及其用途
KR20230152692A (ko) 2021-02-02 2023-11-03 리미널 바이오사이언시스 리미티드 Gpr84 길항제 및 이의 용도
EP4288427A1 (en) 2021-02-02 2023-12-13 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
WO2022170052A1 (en) 2021-02-05 2022-08-11 Black Diamond Therapeutics, Inc. Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
US12252488B2 (en) 2021-02-12 2025-03-18 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
IL304905A (en) 2021-02-15 2023-10-01 Kymera Therapeutics Inc IRAK4 joints and their uses
JP2024506656A (ja) 2021-02-15 2024-02-14 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ４分解剤およびその使用
EP4295850A4 (en) 2021-02-16 2025-03-05 Ribotech Co., Ltd. COMPOUND FOR INHIBITING NONSENSE-MEDIATED mRNA DEGRADATION
AU2022227021A1 (en) 2021-02-26 2023-09-21 Kelonia Therapeutics, Inc. Lymphocyte targeted lentiviral vectors
WO2022187856A1 (en) 2021-03-05 2022-09-09 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
US12071442B2 (en) 2021-03-29 2024-08-27 Nimbus Saturn, Inc. Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
WO2022217276A1 (en) 2021-04-09 2022-10-13 Nimbus Clio, Inc. Cbl-b modulators and uses thereof
AU2022258968A1 (en) 2021-04-16 2023-10-19 Ikena Oncology, Inc. Mek inhibitors and uses thereof
CA3216880A1 (en) 2021-04-16 2022-10-20 Novartis Ag Antibody drug conjugates and methods for making thereof
CN115232122B (zh) * 2021-04-23 2024-05-31 石药集团中奇制药技术（石家庄）有限公司 炔类化合物及其制备和应用
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
PE20240089A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cancer
MX2023013085A (es) 2021-05-05 2023-11-16 Revolution Medicines Inc Inhibidores de ras.
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof
WO2022250170A1 (en) 2021-05-28 2022-12-01 Taiho Pharmaceutical Co., Ltd. Small molecule inhibitors of kras mutated proteins
WO2023284730A1 (en) 2021-07-14 2023-01-19 Nikang Therapeutics, Inc. Alkylidene derivatives as kras inhibitors
JP2024529474A (ja) 2021-07-28 2024-08-06 セロ・セラピューティクス・インコーポレイテッド キメラＴｉｍ４受容体およびその使用
EP4392421A1 (en) 2021-08-25 2024-07-03 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
JP2024534127A (ja) 2021-08-25 2024-09-18 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023076556A1 (en) 2021-10-29 2023-05-04 Kymera Therapeutics, Inc. Irak4 degraders and synthesis thereof
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
KR20240130085A (ko) 2021-12-30 2024-08-28 상하이 한서 바이오메디컬 컴퍼니 리미티드 트리시클릭 유도체 억제제, 이의 제조 방법 및 응용
JP2025504059A (ja) 2022-01-31 2025-02-06 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋデグレーダー及びその使用
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
JP2025509217A (ja) 2022-03-07 2025-04-11 アムジエン・インコーポレーテツド ４－メチル－２－プロパン－２－イル－ピリジン－３－カルボニトリルを調製するための方法
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
US12331026B2 (en) 2022-03-28 2025-06-17 Nikang Therapeutics, Inc. Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
US11878958B2 (en) 2022-05-25 2024-01-23 Ikena Oncology, Inc. MEK inhibitors and uses thereof
WO2023240024A1 (en) 2022-06-08 2023-12-14 Nikang Therapeutics, Inc. Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
CN120504682A (zh) 2022-06-10 2025-08-19 锐新医药公司 大环ras抑制剂
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
EP4565568A1 (en) 2022-08-02 2025-06-11 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
JP2025527248A (ja) 2022-08-02 2025-08-20 リミナル・バイオサイエンシーズ・リミテッド 置換ピリドンｇｐｒ８４アンタゴニスト及びその使用
IL320217A (en) 2022-10-14 2025-06-01 Black Diamond Therapeutics Inc Methods for treating cancer using isoquinoline or 6-azaquinoline derivatives
AU2023375457A1 (en) 2022-11-11 2025-05-01 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
US20240208961A1 (en) 2022-11-22 2024-06-27 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
AU2024253668A1 (en) 2023-04-07 2025-11-13 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
US20240352038A1 (en) 2023-04-14 2024-10-24 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
CN121100123A (zh) 2023-04-14 2025-12-09 锐新医药公司 Ras抑制剂的结晶形式
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
IL321486A (en) 2023-06-23 2025-08-01 Kymera Therapeutics Inc Iraqi joints and their uses
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202515582A (zh) 2023-08-24 2025-04-16 日商大塚製藥股份有限公司 西區嘧啶(cedazuridine)之固定劑量組合
TW202529769A (zh) 2023-09-21 2025-08-01 日商武田藥品工業股份有限公司 Ｔｙｋ２抑制劑及其用途
WO2025072462A1 (en) 2023-09-27 2025-04-03 Nikang Therapeutics, Inc. Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
TW202535891A (zh) 2023-10-20 2025-09-16 美商默沙東有限責任公司 Ｋｒａｓ蛋白之小分子抑制劑
TW202527955A (zh) 2023-11-27 2025-07-16 美商尼坎醫療公司 用於經由泛素蛋白酶體途徑降解週期蛋白依賴性激酶２和週期蛋白依賴性激酶４的含有２，５－取代的嘧啶衍生物的雙功能化合物
WO2025117981A1 (en) 2023-12-02 2025-06-05 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025212828A1 (en) 2024-04-03 2025-10-09 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway
WO2025240536A1 (en) 2024-05-15 2025-11-20 Nikang Therapeutics, Inc. Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and/or cyclin-dependent kinase 4 via ubiquitin proteasome pathway
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
GB8916480D0 (en) 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
PT100441A (pt) 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
US5451700A (en) 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
EP0636026B1 (en) 1992-04-02 2001-12-05 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
JP3192424B2 (ja) 1992-04-02 2001-07-30 スミスクライン・ビーチャム・コーポレイション アレルギーまたは炎症疾患の治療用化合物
MX9301943A (es) 1992-04-02 1994-08-31 Smithkline Beecham Corp Compuestos.
TW225528B (it) 1992-04-03 1994-06-21 Ciba Geigy Ag
EP1238986B1 (en) 1992-10-28 2008-06-25 Genentech, Inc. Use of Vascular endothelial cell growth factor antagonists
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9414208D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DK0836605T3 (da) 1995-07-06 2002-05-13 Novartis Ag Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
SK284073B6 (sk) 1996-04-12 2004-09-08 Warner-Lambert Company Polycyklické zlúčeniny, ich použitie a farmaceutické kompozície na ich báze
WO1997049688A1 (en) 1996-06-24 1997-12-31 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DE69724269T2 (de) 1996-09-06 2004-06-09 Obducat Ab Verfahren für das anisotrope ätzen von strukturen in leitende materialien
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
CN100344627C (zh) 1996-11-18 2007-10-24 生物技术研究有限公司(Gbf) 埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723589D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723566D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
CO4990969A1 (es) 1998-02-14 2000-12-26 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
ATE307123T1 (de) 1998-02-25 2005-11-15 Sloan Kettering Inst Cancer Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813565D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813540D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
CN1313861A (zh) 1998-06-23 2001-09-19 葛兰素集团有限公司 2－(嘌呤－9－基)－四氢呋喃－3,4－二醇衍生物
JP4369053B2 (ja) 1998-06-30 2009-11-18 ダウ グローバル テクノロジーズ インコーポレイティド ポリマーポリオール及びその製造方法
EP1107964B8 (en) 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
ES2264826T3 (es) 1998-10-16 2007-01-16 Pfizer Inc. Derivados de adenina.
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
EP1135470A2 (en) 1998-11-20 2001-09-26 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
EP2016953A3 (en) 1998-12-22 2009-04-15 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
EP1165085B1 (en) 1999-03-30 2006-06-14 Novartis AG Phthalazine derivatives for treating inflammatory diseases
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
IL145741A0 (en) 1999-05-04 2002-07-25 Schering Corp Piperazine derivatives useful as ccrs antagonists
KR100439357B1 (ko) 1999-05-04 2004-07-07 쉐링 코포레이션 Ｃｃｒ５ 길항제로서 유용한 피페리딘 유도체
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CZ302882B6 (cs) 1999-08-21 2012-01-04 Nycomed Gmbh Farmaceutický prostredek
CO5180581A1 (es) 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
GB9924363D0 (en) 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
EP1269999B1 (en) 2000-03-17 2013-05-01 Hisamitsu Pharmaceutical Co. Inc. Ultraviolet-shielding patch
TWI227240B (en) 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives
GB0015727D0 (en) 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
EA005520B1 (ru) 2000-06-27 2005-04-28 Лабораториос С.А.Л.В.А.Т.,С.А. Карбаматы, полученные из арилалкиламинов
KR100787073B1 (ko) 2000-06-28 2007-12-21 글리코파이, 인크. 변형된 당단백질의 제조방법
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
SI1305329T2 (sl) 2000-08-05 2015-07-31 Glaxo Group Limited S-fluorometil ester 6alfa,9alfa-difluoro-17alfa-(2-furanilkarboksil)oksi-11beta-hidroksi- 16alfa-metil-3-okso-androst-1,4-dien-17-karbotiojske kisline kot protivnetno sredstvo
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
KR100869722B1 (ko) 2000-12-22 2008-11-21 알미랄 에이쥐 퀴누클리딘 카르바메이트 유도체 및 ｍ3 길항제로서 그의사용
NZ526674A (en) 2000-12-28 2005-03-24 Almirall Prodesfarma Ag Novel quinuclidine derivatives and medicinal compositions containing the same
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
CA2445839A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
US20040171576A1 (en) 2001-05-25 2004-09-02 Michael Yeadon Adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases
EP2319919B1 (en) 2001-06-21 2015-08-12 BASF Enzymes LLC Nitrilases
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
JP2005512974A (ja) 2001-10-17 2005-05-12 ユ セ ベ ソシエテ アノニム キヌクリジン誘導体、その調製方法、及びｍ２及び／又はｍ３ムスカリン受容体阻害剤としてのその使用
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
MY130622A (en) 2001-11-05 2007-07-31 Novartis Ag Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
AU2002356759A1 (en) 2001-12-01 2003-06-17 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
RS52522B (sr) 2001-12-20 2013-04-30 Chiesi Farmaceutici S.P.A. Derivati 1-alkil-1-azoniabiciklo/2.2.2./oktan karbamata i njihova upotreba kao antagonista muskarinskih receptora
WO2003072592A1 (en) 2002-01-15 2003-09-04 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
AU2003201693A1 (en) 2002-01-21 2003-09-02 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
GB0202216D0 (en) 2002-01-31 2002-03-20 Glaxo Group Ltd Novel compounds
JP2005521717A (ja) 2002-03-26 2005-07-21 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用
DE60318188T2 (de) 2002-03-26 2008-12-11 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Glucocorticoid-mimetika, deren herstellung, pharmazeutische zusammensetzungen und verwendung
US20090170803A1 (en) 2002-04-10 2009-07-02 Linden Joel M Adjunctive treatment of biological diseases
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
ES2201907B1 (es) 2002-05-29 2005-06-01 Almirall Prodesfarma, S.A. Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos.
DE10224888A1 (de) 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10225574A1 (de) 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloxime
DE10227269A1 (de) 2002-06-19 2004-01-08 Merck Patent Gmbh Thiazolderivate
US7153968B2 (en) 2002-06-25 2006-12-26 Merck Frosst Canada, Ltd. 8-(biaryl)quinoline PDE4 inhibitors
JP2005538972A (ja) 2002-07-02 2005-12-22 メルク フロスト カナダ アンド カンパニー ジアリール置換エタンピリドンｐｄｅ４阻害剤
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
EP1521733B1 (en) 2002-07-08 2014-08-20 Pfizer Products Inc. Modulators of the glucocorticoid receptor
AR040962A1 (es) 2002-08-09 2005-04-27 Novartis Ag Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto
US20060094710A1 (en) 2002-08-10 2006-05-04 Altana Pharma Ag Piperidine-pyridazones and phthalazones as pde4 inhibitors
AU2003255376A1 (en) 2002-08-10 2004-03-11 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
CA2494643A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-n-oxide-derivatives
WO2004018451A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Pyridazinone-derivatives as pde4 inhibitors
AU2003263216A1 (en) 2002-08-17 2004-03-11 Nycomed Gmbh Benzonaphthyridines with PDE 3/4 inhibiting activity
AU2003253408A1 (en) 2002-08-17 2004-03-11 Nycomed Gmbh Novel phenanthridines
SE0202483D0 (sv) 2002-08-21 2002-08-21 Astrazeneca Ab Chemical compounds
EP1534675B1 (en) 2002-08-23 2009-02-25 Ranbaxy Laboratories, Ltd. Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo¬3.1.0 hexane derivatives as muscarinic receptor antagonists
US7423046B2 (en) 2002-08-29 2008-09-09 Nycomed Gmbh 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
AU2003255493B8 (en) 2002-08-29 2009-03-26 Takeda Gmbh 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors
JP2006096662A (ja) 2002-09-18 2006-04-13 Sumitomo Pharmaceut Co Ltd 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤
US20050267114A1 (en) 2002-09-18 2005-12-01 Yoshikazu Takaoka Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
JP2004107299A (ja) 2002-09-20 2004-04-08 Japan Energy Corp 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤
DE10246374A1 (de) 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE60317918T2 (de) 2002-10-23 2009-01-29 Glenmark Pharmaceuticals Ltd. Tricyclische verbindungen zur behandlung von entzündlichen und allergischen erkrankungen verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
DE10253426B4 (de) 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
DE10253220A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
SI1585749T1 (sl) * 2003-01-09 2008-10-31 Pfizer Derivati diazepinoindola kot inhibitorji kinaze
EP1452173A1 (de) 2003-02-25 2004-09-01 Schering AG UV-stabiles transdermales Pflaster
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
AR046845A1 (es) 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
PT1687305E (pt) * 2003-11-21 2008-10-17 Novartis Ag Derivados de 1h-imidazoquinolina como inibidores de proteína quinase
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
HK1115871A1 (en) 2008-12-12
HK1151286A1 (en) 2012-01-27
WO2006122806A3 (en) 2009-03-12
ZA200709074B (en) 2008-11-26
AR086528A2 (es) 2013-12-18
CN102796099A (zh) 2012-11-28
DK2292617T3 (da) 2012-10-08
EP1888578A2 (en) 2008-02-20
PT2270008E (pt) 2013-01-22
US7994170B2 (en) 2011-08-09
EP2270008B8 (en) 2013-04-03
BRPI0610321A2 (pt) 2010-06-15
GB0510390D0 (en) 2005-06-29
US20080194579A1 (en) 2008-08-14
US20120207751A1 (en) 2012-08-16
US20110251202A1 (en) 2011-10-13
BRPI0610321B8 (pt) 2021-05-25
EA013434B1 (ru) 2010-04-30
CY1112369T1 (el) 2015-12-09
TW200724541A (en) 2007-07-01
EP2270008B1 (en) 2012-10-03
PE20070004A1 (es) 2007-01-30
EP2292617B1 (en) 2012-07-11
HRP20130799T1 (en) 2013-09-30
KR20080009724A (ko) 2008-01-29
IL187003A (en) 2014-09-30
DK2270008T3 (da) 2013-01-14
EP1888578B9 (en) 2012-04-25
US8431592B2 (en) 2013-04-30
ES2378463T3 (es) 2012-04-12
JO2751B1 (en) 2014-03-15
CY1113494T1 (el) 2016-06-22
JP5508485B2 (ja) 2014-05-28
CA2608496A1 (en) 2006-11-23
MA29462B1 (fr) 2008-05-02
TNSN07431A1 (en) 2009-03-17
AU2006249071B2 (en) 2010-04-01
PL1888578T3 (pl) 2012-05-31
SMAP200700051A (it) 2007-11-28
ES2391161T3 (es) 2012-11-22
SI2270008T1 (sl) 2013-01-31
US20100056558A1 (en) 2010-03-04
TWI383982B (zh) 2013-02-01
CN101495477A (zh) 2009-07-29
GEP20105054B (en) 2010-07-26
PT1888578E (pt) 2012-02-20
NZ562890A (en) 2010-12-24
WO2006122806A2 (en) 2006-11-23
AU2006249071A1 (en) 2006-11-23
AR054127A1 (es) 2007-06-06
MX2007014380A (es) 2008-02-11
IL221573A0 (en) 2012-10-31
CR9504A (es) 2008-07-31
UA92490C2 (en) 2010-11-10
JP2008540599A (ja) 2008-11-20
NO20076561L (no) 2008-01-14
MY147442A (en) 2012-12-14
IL187003A0 (en) 2008-02-09
ATE535526T1 (de) 2011-12-15
JP2012255008A (ja) 2012-12-27
ES2397081T3 (es) 2013-03-04
PL2270008T3 (pl) 2013-02-28
EP1888578B8 (en) 2013-04-03
IL221573A (en) 2016-02-29
EP1888578B1 (en) 2011-11-30
NI200700296A (es) 2008-07-24
SI1888578T1 (sl) 2012-02-29
BRPI0610321B1 (pt) 2020-10-06
EP2270008A1 (en) 2011-01-05
GT200600193A (es) 2007-01-15
JP5220591B2 (ja) 2013-06-26
EP2292617A1 (en) 2011-03-09
CA2608496C (en) 2013-06-18
HRP20130794T1 (en) 2013-09-30
US7667039B2 (en) 2010-02-23
DK1888578T3 (da) 2012-02-20
KR101237575B1 (ko) 2013-02-26
EA200702387A1 (ru) 2008-06-30
NO340584B1 (no) 2017-05-15

Similar Documents

Publication Publication Date Title
SMP200700051B (it) Imidazochinoline come inibitori di lipide chinasi
CY2021013I1 (el) Δι-αρυλ μετα-πυριμιδινο αναστολεις κινασων
SMAP200800022A (it) Benzimidazoli sostituiti come inibitori delle chinasi
IL184674A0 (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
IL186845A0 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
NO20082514L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
CR10369A (es) Pyrimidine derivatives as pi3k inhibitors
ATE517886T1 (de) Pyrazolderivate
BRPI0716781A2 (pt) Inibidores da quinase
ATE506358T1 (de) 2-benzylpyridazinonderivate als met-kinasehemmer
DK1943243T3 (da) Kinase-inhibitorer
ATE433449T1 (de) Kinaseinhibitoren
ZA200800506B (en) Substituted benzimidazoles as kinase inhibitors
DK2170891T3 (da) Pyrazolopyrimidinon-kinasehæmmere
TR200602046A3 (tr) Vitrin
ZA200709732B (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
BRPI0719883A2 (pt) Inibidores de quinase
ZA200706212B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
DE602006019301D1 (de) Kinaseinhibitoren
NO20082419L (no) Pyrazol-isokinolinureaderivater som P38 kinaseinhibitorer
DE602005008061D1 (de) Kinaseinhibitoren
FI6797U1 (fi) Vitriini
EP1940411A4 (en) MACROHETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
UA14251S (uk) Вітрина